CAR T-cell applications for AML have been investigated in vitro and in mice models [5] targeting CD33 [6–9], CD44v6 [10], CD123 [5, 9, 11, 12], but only results from small clinical trials targeting Lewis-Y (LeY) [13], or CD33 [14] have been published to date. Here, CD33 is linked to acute myeloid leukemia.